News

Precision Cancer Test Validated for Clinical Usage

A powerful next-generation genome-sequencing test developed at Weill Cornell Medicine can detect mutations that guide precision cancer treatment with over 95 percent accuracy, according to new research.

NIH awards $4M grant to advance precision medicine

Moving with what has been cited as unprecedented speed, the National Institutes of Health (NIH) has chosen a collaboration of four New York institutions -- Weill Cornell Medicine, NewYork-Presbyterian Hospital, Columbia University Hospital and NYC Health + Hospitals/Harlem -- to launch a landmark

Sequencing Reveals Molecular Underpinnings of Aggressive Prostate Cancer Subtype

A subset of treatment-resistant prostate cancer pathologically resembles small cell lung cancer rather than typical prostate cancer, Weill Cornell Medicine and